^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PLCG2 mutation

    i
    Other names: PLCG2, Phospholipase C Gamma 2, 1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Gamma-2, Phospholipase C, Gamma 2 (Phosphatidylinositol-Specific), Phosphoinositide Phospholipase C-Gamma-2, Phospholipase C-IV, PLC-Gamma-2, PLC-IV, Phospholipase C-Gamma-2, APLAID, FCAS3
    Entrez ID:
    5336
    Related biomarkers:
    Mutation
    Apply
    Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (TRANSCEND-CLL-004) (NCT03331198)
    Phase 1/2
    Juno Therapeutics, a Subsidiary of Celgene
    Active, not recruiting
    Last update posted :
    03/17/2023
    Initiation :
    11/27/2017
    Primary completion :
    02/28/2027
    Completion :
    02/28/2027
    CD19 • PLCG2 • CD5
    |
    CD19 positive • PLCG2 mutation
    |
    Venclexta (venetoclax) • ibrutinib • Breyanzi (lisocabtagene maraleucel) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Dasatinib In Waldenström Macroglobulinemia (NCT04115059)
    Phase 1
    Jorge J. Castillo, MD
    Recruiting
    Last update posted :
    03/24/2022
    Initiation :
    11/04/2019
    Primary completion :
    03/01/2022
    Completion :
    03/01/2024
    MYD88 • PLCG2
    |
    MYD88 mutation • PLCG2 mutation
    |
    dasatinib • ibrutinib • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)